Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
Status:
Completed
Trial end date:
2019-02-07
Target enrollment:
Participant gender:
Summary
This is a Phase I, open label, Dose Escalation study of oral administration of single agent
MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in
participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have
measurable disease.